Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

299
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
299
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

295
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
295
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

295
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
295
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

320
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
320
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

503
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
503
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

102
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
102

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Weight Trajectories in Infants Receiving Prolonged Breastfeeding: Impact of Formula Supplementation.

Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine·2026
Same author

Tasty&Healthy exclusive whole food diet in asymptomatic children and young adults with biologically active Crohn's disease: the TASTI-E randomized controlled trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Histological activity predicts relapse in pediatric ulcerative colitis despite mucosal healing: a multicenter study from the pediatric IBD Porto group of ESPGHAN.

Journal of Crohn's & colitis·2026
Same author

Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN.

Inflammatory bowel diseases·2026
Same author

Multi-omics-based machine learning model predicts response and guides treatment in Crohn disease: a case study in nutritional therapy.

Inflammatory bowel diseases·2026
Same author

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same journal

Comparison of the effectiveness of two active distraction methods in reducing pain, fear, and anxiety in children during venipuncture: a randomized controlled trial.

BMC pediatrics·2026
Same journal

Current approaches to acute bronchiolitis management among pediatricians: guideline adherence and practice variation.

BMC pediatrics·2026
Same journal

Demographic and histopathological evaluation of thymus in 1173 cases of cyanotic and acyanotic congenital heart diseases.

BMC pediatrics·2026
Same journal

Performance evaluation of low-volume blood collection tubes for coagulation tests.

BMC pediatrics·2026
Same journal

A randomized clinical trial comparing the efficacy of probiotic drops and sucrose in managing colic in early infancy.

BMC pediatrics·2026
Same journal

Restless senses, restless sleep: Exploring the sensory-sleep link in Phelan-McDermid syndrome. A Cross-Sectional Exploratory Study.

BMC pediatrics·2026
See all related articles

Related Experiment Video

Updated: Nov 18, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.7K

Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD.

Gil Berkovitch1, Shlomi Cohen2, Ronit Lubetzky3,4

  • 1Pediatric Gastroenterology Unit, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.

BMC Pediatrics
|February 5, 2021
PubMed
Summary
This summary is machine-generated.

Biologic therapy did not change why children were hospitalized for inflammatory bowel disease (IBD). However, it was linked to fewer hospitalizations for pediatric IBD patients between 2016-2019.

Keywords:
Biologic therapyChildrenCrohn’s diseaseHospitalizationInflammatory bowel diseaseUlcerative colitis

More Related Videos

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.5K

Related Experiment Videos

Last Updated: Nov 18, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.7K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

11.9K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.5K

Area of Science:

  • Pediatric Gastroenterology
  • Immunology
  • Clinical Therapeutics

Background:

  • The impact of biologic therapy on inflammatory bowel disease (IBD) hospitalizations remains debated.
  • Existing research lacks data on how biologic agents affect hospitalization indications in IBD.
  • This study investigates the influence of biologic therapy on hospitalization rates and reasons in pediatric IBD patients.

Purpose of the Study:

  • To assess the effect of biologic therapy on hospitalization indications in pediatric IBD.
  • To determine if biologic agents alter the rate of hospitalizations in children with IBD.

Main Methods:

  • A retrospective cohort study analyzed 218 hospitalizations in 100 pediatric IBD patients (under 18) from 2004-2019.
  • Data collected included demographics, disease characteristics, therapy, and hospitalization indications/outcomes.
  • Multivariate analysis examined the relationship between biologic therapy and hospitalization patterns.

Main Results:

  • Hospitalizations were primarily due to IBD exacerbations/complications (89%) rather than therapy side effects (11%).
  • No correlation was found between biologic therapy and the indication for hospitalization (p=0.829).
  • A significant decrease in hospitalization rates was observed in pediatric IBD patients on biologic therapy from 2016-2019 (1.09 to 0.27 per year, p=0.043).

Conclusions:

  • Biologic therapy does not appear to influence the reasons for hospitalization in pediatric IBD.
  • Biologic agents are associated with a reduced rate of hospitalization in pediatric IBD patients.
  • Findings suggest a beneficial effect of biologics on reducing hospitalization frequency in this population.